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Abstract
Cellular homeostasis relies on a tight control of protein synthesis, folding and degradation, in which the endoplasmic
reticulum (ER) quality control and the ubiquitin proteasome system (UPS) have an instrumental function. ER stress and
aberrant accumulation of misfolded proteins represent a pathological signature of amyotrophic lateral sclerosis (ALS), a fatal
paralytic disorder caused by the selective degeneration of motoneurons in the brain and spinal cord. Mutations in the ER-
resident protein VAPB have been associated with familial forms of the disease. ALS-linked mutations cause VAPB to form
cytoplasmic aggregates. We previously demonstrated that viral-mediated expression of both wildtype and mutant human
VAPB (hVAPB) leads to an ER stress response that contributes to the selective death of motoneurons. However, the
mechanisms behind ER stress, defective UPS and hVAPB-associated motoneuron degeneration remain elusive. Here, we
show that the overexpression of wildtype and mutated hVAPB, which is found to be less stable than the wildtype protein,
leads to the abnormal accumulation of ubiquitin and ubiquitin-like protein conjugates in non-human primate cells. We
observed that overexpression of both forms of hVAPB elicited an ER stress response. Treatment of wildtype and mutated
hVAPB expressing cells with the ER stress inhibitor salubrinal diminished the burden of ubiquitinated proteins, suggesting
that ER stress contributes to the impairment of proteasome function. We also found that both wildtype and mutated hVAPB
can associate with the 20S proteasome, which was found to accumulate at the ER with wildtype hVAPB or in mutant hVAPB
aggregates. Our results suggest that ER stress and corruption of the proteasome function might contribute to the aberrant
protein homeostasis associated with hVAPB.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurode-
generative disease, which primarily affects motoneurons in the
cortex, brainstem and spinal cord. Symptoms begin with a focal
muscle weakness and wasting, which irrevocably spreads to
complete paralysis and leads to death within 3 to 5 years. ALS
occurs either in a predominant sporadic form, or less frequently, in
an inherited, familial form, both being clinically indistinguishable.
Like in many other neurodegenerative disorders, neuronal
cytoplasmic proteinaceous aggregates are a pathological signature
of the disease. These protein deposits, referred to as Bunina
bodies, Lewy body-like or hyaline inclusions are suggested to play
a decisive role in the pathogenesis of both sporadic and familial
ALS [1,2].
In healthy cells, protein quality control systems in the cytoplasm
and endoplasmic reticulum (ER) ensure a tight regulation of
protein concentration and folding through selective clearance
mechanisms. In particular, the proteasome, a large multicatalytic
complex, plays an instrumental role in eliminating improperly
folded or damaged proteins. Proteins targeted for destruction are
covalently marked at lysine residues by ubiquitin, a 76 amino-acid
polypeptide, through multi-enzymatic sequential transfer in order
to be recognized by the proteasomal degradative machinery [3].
An impairment of the ubiquitin-proteasome system (UPS) has
been proposed to lead to the accumulation of ubiquitin-conjugated
proteins and the formation of aggregates [4,5]. In both familial
and sporadic ALS as well as in a proportion of ALS with
frontotemporal dementia (FTD), inclusions immunoreactive for
ubiquitin are observed in motoneurons [6,7,8,9]. However, the
mechanisms by which ALS-causing factors compromise protein
homeostasis and lead to intracellular aggregates remain elusive.
Mutations in the vesicle-associated membrane protein (VAMP)-
associated protein B (VAPB) have been associated with ALS [10].
VAPB is a type II integral membrane protein that mainly locates
at the endoplasmic reticulum (ER). VAPB has been proposed to
act in the regulation of COPI-mediated protein transport within
the Golgi apparatus and from the Golgi back to the ER [11].
VAPB has been documented to maintain the structural and
functional integrity of the Golgi through the control of lipid
transport [12], and of the ER probably through its bridging to the
microtubule network [13]. Another VAPB function relates to the
modulation of the unfolded protein response (UPR), though the
precise role of VAPB in the control of the UPR remains unclear
[14,15,16,17].
The two ALS-associated missense mutations (P56S and T46I) in
VAPB that have been identified so far lead to the formation of
dense and insoluble cytosolic VAPB aggregates [10,18]. The
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formation of aberrant ER structures [19,20,21] and an ineffectual
UPR [14,15,16,17,18]. We demonstrated that the overexpression
of both wildtype and mutated VAPB disturbs Ca
2+ homeostasis in
motoneurons and that this contributes to their selective degener-
ation [17]. Ubiquitinated aggregates are also found in cells
expressing VAPB mutants, though these aggregates do not or only
rarely colocalize with VAPB aggregates in mammalian cells
[18,21], as well as in spinal motoneurons of mutated VAPB
transgenic mice [22]. This observation suggests that a more global
alteration of the protein clearance system could participate in the
pathogenic mechanisms of VAPB.
Here, we show that the overexpression of both wildtype and
mutated hVAPB leads to the accumulation of proteins targeted for
proteasomal degradation. We provide evidence that the ER stress
response elicited by the forced expression of hVAPB
WT and
hVAPB
P56S partiallycompromisestheproteinclearancemachinery.
In addition, we found that both forms of hVAPB interact with the
proteasome suggesting that another inhibitory mechanism of
proteasomal activity could include the trapping of the proteasome.
We propose that disturbance of the UPS activity that might occur
through ER stress and sequestration of the proteasome contributes
to the pathogenic process in VAPB-associated motoneuron disease.
Results
hVAPB localizes at the ER and with components of the
secretory pathway
To better understand the biochemical properties of human VAPB
(hVAPB
WT) and its ALS-associated P56S mutated form
(hVAPB
P56S), we expressed them in the highly transfectable non-
human primate COS-7 cell line. We first investigated their
subcellular localization by immunocytochemistry using an antibody
specifically raised against the human form of VAPB [17] and
antibodies or fluorescent constructs that specifically label compart-
ments of the secretory pathway. We found that hVAPB
WT
colocalized with the ER marker KDEL (Figure 1A), the COPI
vesiclemarkerb-COP-cyanfluorescentprotein(CFP)[23](Figure1B)
and the ER-Golgi intermediate compartment (ERGIC) marker
ERGIC-53 (Figure 1C). By contrast, we observed a sparse
colocalization of hVAPB
WT with Sec23, a marker of COPII vesicles
[24](Figure 1D). As previously described [10,15,17,21], the presence
of the P56S mutation led to the formation of hVAPB cytoplasmic
aggregates. We found that these hVAPB
P56S aggregates colocalized
with KDEL, b-COP, ERGIC-53 but poorly colocalized with Sec23
in COS-7 cells (Figure 1A–D). We did not observe any co-
immunolocalization of hVAPB
WT or hVAPB
P56S with the Golgi
marker GM-130 (data not shown).
To examine further hVAPB
P56S accumulation in COS-7 cells,
we conducted differential detergent extraction to analyze its
solubility profile. Cells expressing hVAPB
WT and hVAPB
P56S
were first solubilized in a non-ionic detergent (1% Triton X-100)
and subjected to high-speed centrifugation. Detergent-resistant
fractions were then sequentially extracted in an ionic detergent
(1% sodium dodecyl sulfate, SDS) and under chaotropic
conditions (8 M urea). Extracted proteins were then separated
by SDS-PAGE and analyzed by immunoblotting with hVAPB
specific antibodies. We detected the wildtype protein in the Triton
X-100 fraction at 12, 24, 48 and 72 h following transfection. At
72 h, we observed that a significant proportion of the wildtype
protein was retrieved in the SDS fraction (Figure 2A). When we
performed sequential protein extraction on hVAPB
P56S-expressing
COS-7 cells, we found that at all time points, the mutated protein
was only found in the SDS-soluble fractions. It is of note that, for
both forms of hVAPB, we did not observe the presence of high
molecular weight species in the different fractions nor any cleaved
fragment (data not shown)[25]. In addition, no hVAPB immuno-
reactivity was ever found in the urea-soluble fractions over time
(Figure 2A). To complement this solubility analysis by immuno-
blotting, an immunocytochemical study of hVAPB
WT at 72 h
shows the presence of large cytoplasmic inclusions and a marked
disruption of the ER structure, as illustrated by KDEL
immunostaining (Figure 2B). At this time of analysis, the
immunoreactive profile of hVAPB
P56S aggregates was not notably
different from earlier time points and no marked disruption of the
ER structure was observed (Figure 2B). In conclusion, we
confirmed that, in the COS-7 cell line, wildtype hVAPB mainly
localizes at the ER and in compartments of the secretory pathway
and that the P56S mutation leads to its insolubility and to the
formation of cytoplasmic aggregates. Interestingly, in our in vitro
system, we found that persistent expression of wildtype VAPB also
leads to its insolubility and affects ER integrity.
The ALS-linked P56S mutation decreases the stability of
hVAPB
We nextstudied the stability of both wildtype and mutated VAPB
by analyzing their rate of decay following inhibition of neosynthesis
by the translational inhibitor cycloheximide (CHX). Transfected
cells were treated with CHX for different times before being
harvested at 36 h post-transfection and levels of both hVAPB
WT
and hVAPB
P56S were analyzed by Western blotting. We found that
after 10 h of CHX treatment, levels of mutated hVAPB were
significantly lower than those of the wildtype protein (Figure 3A–C).
We were not able to study the effect of a longer treatment due to a
significant toxicity of CHX after 10 h (data not shown).
We next asked whether the decreased stability of hVAPB
P56S
was due to its degradation by the proteasome. Toward this goal,
we used the selective proteasome inhibitor MG-132 in combina-
tion with CHX in cells transfected with wildtype or mutated
hVAPB. Cells were harvested for immunoblot analysis after 10 h
of treatment. We found that the addition of MG-132 concomitant
with the inhibition of neosynthesis by CHX partially prevented the
degradation of hVAPB
P56S but had no effect on hVAPB
WT levels
(Figure 3A, 3C). We confirmed that at this dose, MG-132
efficiently blocks proteasome activity with a limited effect on cell
viability (see below). Remarkably, when we analyzed the
localization of hVAPB
WT and hVAPB
P56S by immunocytochem-
istry, we observed that the inhibition of proteasome activity
induced a typical perinuclear accumulation of hVAPB
P56S
aggregates while the localization of the wildtype protein was not
significantly affected (Figure 3D–E). This suggests that proteasome
activity partially influences the levels and cytoplasmic scattering of
hVAPB
P56S aggregates in mammalian cells.
hVAPB
WT and hVAPB
P56S increase levels of ubiquitinated
conjugates
We next sought to examine the ubiquitination profile of
mutated hVAPB compared to the wildtype protein. To visualize
ubiquitination, we co-expressed either the wildtype or the mutated
form of hVAPB with a green fluorescent protein (GFP)-tagged
ubiquitin (GFP-Ubi). The GFP-Ubi chimeric protein has been
demonstrated to be covalently incorporated into ubiquitin target
proteins and to efficiently trace them [26]. When expressed alone,
GFP-Ubi reflected the basal ubiquitination process in COS-7 cells
with a diffuse cellular fluorescence (Figure 4A). By contrast, when
GFP-Ubi was co-expressed with either hVAPB
WT or hVAPB
P56S,
we observed an increased accumulation of ubiquitin-positive
VAPB Compromises Proteasome Activity
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WT and
hVAPB
P56S (Figure 4A). As a control, we used a mutated version
of the GFP moiety (GFP-UbiAA) that cannot get incorporated into
ubiquitinated proteins [26]. Consistently, GFP-UbiAA failed to
form GFP-positive cytoplasmic aggregates both in hVAPB
WT and
hVAPB
P56S expressing cells (Figure 4B). Taken together, these
results suggest that wildtype and mutated forms of hVAPB are not
major ubiquitination substrates and that an alternative degrada-
tion pathway may exist to maintain hVAPB protein homeostasis.
We next examined the detergent solubility features of the
ubiquitin conjugates in cells expressing hVAPB
WT and
hVAPB
P56S. Differential detergent extraction and Western blot
analyzes of ubiquitin first confirmed that both forms of hVAPB
caused an increase in the total levels of ubiquitin-conjugated
proteins (Figure 4C). However, only the overexpression of mutated
hVAPB led to the formation of Triton X-100 insoluble ubiquitin-
conjugates. Finally, we evaluated whether the expression of
hVAPA, an ER-resident VAP family member that has not been
associated with motoneuron disease, leads to a global augmenta-
tion of ubiquitin conjugates. Consistent with our previous data, we
found that the overexpression hVAPB
WT and hVAPB
P56S
increased the levels of ubiquitinated proteins. By comparison,
hVAPA overexpression affected to a lesser extent levels of high
molecular weight ubiquitin conjugates (Figure 4D), suggesting that
this effect on the overall ubiquitination is preferential to hVAPB.
Accumulation of hVAPB
WT and hVAPB
P56S impairs
ubiquitin- and ubiquitin-like dependent proteasomal
degradation
We next investigated whether the elevated levels of ubiquitin-
protein conjugates observed following hVAPB
WT and hVAPB
P56S
expression involve an impairment of proteasomal degradation.
Figure 1. Wildtype and mutated hVAPB associate with components of the secretory pathway in non-human primate cells. (A–D)
Thirty-six hours following transfection of COS-7 cells, hVAPB
WT and hVAPB
P56S mainly colocalize with components of the secretory pathway as
demonstrated by the immunostaining of hVAPB with the ER marker KDEL (A), the COPI vesicle marker b-COP-CFP (B) and ERGIC marker ERGIC-53 (C).
hVAPB
P56S forms cytoplasmic aggregates that colocalize with ER, COPI and ERGIC markers. Both hVAPB
WT and hVAPB
P56S seldom colocalize (white
arrow) with the COPII marker Sec23-YFP (D). Scale bar, 20 mm.
doi:10.1371/journal.pone.0026066.g001
VAPB Compromises Proteasome Activity
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26066Toward this goal, we took advantage of some well-established
yellow fluorescent protein (YFP)-tagged specific substrates that,
when expressed in living cells, are degraded by the proteasome
through different pathways [27]. Namely, these substrates are Ub-
R-YFP, a short-living cytosolic substrate degraded through the N-
end rule pathway [27,28]. Ub
G76V-YFP, a cytosolic substrate
degraded via the ubiquitin fusion degradation (UFD) system
[27,29] and CD3d-YFP, a T-cell receptor subunit whose
degradation occurs through the ER-associated protein degrada-
tion (ERAD) system, which translocates misfolded protein from
the ER to the cytosol for degradation [30,31]. We determined the
proteolytic activity of the proteasome through Western blot
analysis of YFP levels in cells transiently co-transfected with
plasmids driving expression of the different proteasome substrates
and either hVAPB
WT or hVAPB
P56S. The overexpression of
wildtype and mutated hVAPB increased the steady-state levels of
the three proteasome reporters Ub-R-YFP, Ub
G76V-YFP and
CD3d-YFP (Figure 5A–C). To ensure that the increased
accumulation of the proteasome substrates was not due to an
unspecific effect of protein overload, we co-expressed hVAPA or
the human superoxide dismutase-1 (hSOD1) with the different
proteasome reporters. In these cases, we observed that neither
hVAPA nor hSOD1 overexpression led to an increase in
proteasome substrates as marked as both wildtype or mutated
hVAPB did (Figure 5A–C). These data suggest that overexpression
of both wildtype and mutated forms of hVAPB impair UPS
independently of the pathway leading to proteasomal degradation
(N-end rule, UFD or ERAD).
We next asked whether the negative effect of hVAPB on
proteasome activity was restricted to proteins that depend on
ubiquitin signal for their degradation. F-adjacent transcript-10
(Fat10) is an ubiquitin-like protein that serves as a signal for
degradation by the proteasome [32]. A HA-tagged Fat10 was then
co-expressed with hVAPB
WT, hVAPB
P56S or hVAPA. We found
that co-expression of HA-Fat10 with either hVAPB
WT or
hVAPB
P56S led to an increased accumulation of total HA-Fat10-
conjugated proteins compared to a control empty vector or a
vector expressing hVAPA (Figure 5D). These results indicate that
overexpression of wildtype or mutated hVAPB can impair
proteasome activity independently of the targeting signal.
ER stress contributes to hVAPB-induced impairment of
the proteasome activity
We have recently demonstrated that adeno-associated virus
(AAV)-mediated expression of wildtype and mutated hVAPB in
motoneurons leads to an ER stress response that contributes to
neurodegeneration [17]. It has been shown that ER stress may
impede UPS activity [30]. This prompted us to examine whether
the impairment of proteasome activity following hVAPB
WT or
hVAPB
P56S overexpression is caused by ER stress. We first
evaluated whether overexpression of hVAPB
WT and hVAPB
P56S
elicits an ER stress response in COS-7 cells by analyzing the
induction of the ER stress marker C/EBP-homologous protein
(CHOP)[33]. As depicted in Figure 6A, we observed a marked
increase of CHOP protein in cells expressing wildtype and
mutated hVAPB. Furthermore, we show that the overexpression
of both wildtype and mutated hVAPB leads to the induction of the
immunoglobulin binding protein, BiP, as well as an increased
phosphorylation of the inositol-requiring enzyme 1 (IRE1); two
ER stress markers [34,35](Figure 6B). We next evaluated whether
ER stress compromises UPS activity in COS-7 cells by analyzing
the proteasome reporter (Ub-R-YFP and Ub
G76V-YFP) levels. We
Figure 2. Accumulation of hVAPB
WT leads to the formation of cytoplasmic inclusions. (A) Sequential detergent extraction of cellular
proteins at different times following transfection of COS-7 cells with indicated an empty vector, hVAPB
WT and hVAPB
P56S expression vectors. (B)
Accumulation of wildtype hVAPB leads to the formation of insoluble inclusions that disrupt ER structure as documented by the co-immunostaining of
hVAPB with KDEL 72 h after transfection. Scale bar, 20 mm.
doi:10.1371/journal.pone.0026066.g002
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elevated levels of proteasome substrates following treatment with
the ER stress inducer thapsigargin in our experimental conditions
(Figure 6C–D).
We then sought to examine the effect of the ER stress inhibitor
salubrinal on proteasome activity following hVAPB
WT and
hVAPB
P56S overexpression [36]. We first ensured that the dose
of salubrinal we used prevented the increase phosphorylation of
eukaryotic translation initiation factor 2 subunit alpha under stress
condition in COS-7 cells (data not shown). We then found that
salubrinal significantly decreased by 42% and 31% the accumu-
lation of proteasome substrates following overexpression of
hVAPB
WT and hVAPB
P56S respectively (Figure 6E). To further
confirm that hVAPB-mediated ER stress impairs proteasome
activity, we analyzed the overall profile of ubiquitination by
differential detergent extraction and Western blot with anti-
ubiquitin antibodies in COS-7 expressing either form of hVAPB in
the presence of salubrinal. Consistently, we observed that
Figure 3. Mutated hVAPB is degraded faster than wildtype hVAPB through a proteasome-dependent mechanism. (A) Western blot
analysis of COS-7 cells transfected with the indicated expression vectors and treated or not with the protein biosynthesis inhibitor cycloheximide
(CHX, 100 mg/ml) for 3, 6, 8 and 10 h and/or with the proteasome blocking agent MG-132 (10 mM) for 10 h. Actin served as a loading control. (B)
hVAPB immunoreactive bands were quantified by densitometry and values were normalized to actin and expressed relative to values obtained in
untreated cells. (C) Densitometric quantification of hVAPB levels in transfected cells following 10 h of treatment with CHX and MG-132. (D-E)
Immunolabeling of hVAPB in transfected COS-7 cells treated for 12 h with MG-132 (5 mM)(D). The number of cells showing a perinuclear
accumulation of hVAPB was determined 36 h after transfection with the indicated vectors (E). Scale bar, 20 mm. Results shown in (B), (C) and (E) are
the mean values 6 S.D of three independent experiments.
doi:10.1371/journal.pone.0026066.g003
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both Triton X-100 and SDS fractions that accompanied the
overexpression of hVAPB
WT and hVAPB
P56S (Figure 6F). These
results suggest that ER stress contributes to the impairment of UPS
activity induced by overexpression of both wildtype and mutated
form of hVAPB, though other mechanisms might also exist.
Wildtype and mutated hVAPB sequester the proteasome
It has been observed in SOD1 mutant mouse spinal cords that
the 20S proteasome particle was trapped in neuronal inclusions
[37]. We therefore asked whether this histological characteristic
was also shared by another ALS-causing gene and whether the
proteasome could be complexed by hVAPB. We performed an
immunostaining analysis of the alpha 5 subunit of the proteasome
in COS-7 cells expressing wildtype or mutated hVAPB. Interest-
ingly, we found that the proteasome was markedly retained at the
ER in cells overexpressing wildtype hVAPB, and it was also found
sequestered in hVAPB
P56S cytoplasmic aggregates (Figure 7A).
This observation suggests that hVAPB might bind to the
proteasome, either directly or indirectly.
We performed an immunoprecipitation assay of the endogenous
alpha 5 subunit from COS-7 cells expressing hVAPB
WT,
hVAPB
P56S or other proteins used as controls: the COPII coat
protein Sar1, the COPI coat protein ADP-ribosylation factor 1
(Arf1), as well as hSOD1 and hVAPA. We found that both
wildtype and mutated hVAPB immunoprecipitated endogenous
alpha 5, whereas alpha 5 was not found in Sar1, Arf1, hSOD1 or
hVAPA immunoprecipitates (Figure 7B). We did not perform
reverse immunoprecipitation experiments, consisting in the
immunoprecipitation of alpha 5 and the immunodetection of
hVAPB, since hVAPB
P56S aggregates were precipitated by low
centrifuge force (as low as 5006g) independently of sepharose
bead-conjugated immunocomplexes (data not shown). Therefore,
we conducted an immunoprecipitation of hVAPB followed by an
immunoblotting analysis using an antibody that recognizes several
alpha subunits (alpha 1–7) of the 20S proteasome particle.
Figure 4. hVAPB
P56S partially colocalizes with ubiquitinated conjugates but increases the general ubiquitin levels in the cells. (A)
When co-transfected with hVAPB
WT or hVAPB
P56S, GFP-Ubi forms cytoplasmic aggregates that occasionally (white arrow) colocalize with hVAPB
WT or
hVAPB
P56S. (B) The GFP-tagged mutated ubiquitin UbiAA-GFP does not form detectable aggregates. Scale bar, 20 mm. (C) Ubiquitin immunoblot
profile of COS-7 cells transfected with empty, hVAPB
WT and hVAPB
P56S vectors following differential detergent extraction. (D) Western blot analysis of
total HA-tagged ubiquitin levels in cells expressing either form of hVAPB or hVAPA. In (C) and (D), protein extracts were prepared 36 h after
transfection and actin was used as a loading control.
doi:10.1371/journal.pone.0026066.g004
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WT and hVAPB
P56S
were able to co-immunoprecipitate the proteasome (Figure 7C).
By contrast, neither Sar1, Arf1, hSOD1 nor hVAPA was found to
efficiently immunoprecipitate the proteasome. As a positive
control, we observed that Rpt2, a subunit of the 19S regulatory
complex of the proteasome, efficiently co-immunoprecipitated the
alpha subunits of the 20S proteasome core particle (Figure 7C).
However, when hVAPB
WT and hVAPB
P56S expressing cells
were subjected to hVAPB immunoprecipitation, we failed to
observe immunoreactivity for the 19S proteasome subunit Rpt2 or
Rpn10 in the precipitates (data not shown). Altogether, these
results show that both wildtype and mutated hVAPB can be found
in association with the 20S proteasome particle.
Discussion
The pathology of ALS includes a defective protein homeostasis
and the formation of protein aggregates. This led us to study
whether the overexpression of both wildtype and mutated hVAPB,
previously demonstrated to selectively triggers death of motoneu-
rons [17], interferes with protein turnover. We found that the
overexpression of both wildtype and mutated hVAPB impairs
proteasome function and increases the burden of ubiquitin- and
ubiquitin-like conjugates. Our data show that an ER stress
response elicited by the forced expression of both hVAPB
WT and
hVAPB
P56S contributes to the disruption of proteasome activity. In
addition, we found that both wildtype and mutated hVAPB
interact with the 20S proteasome, providing a potential mecha-
nism of UPS impairment.
Protein aggregates have already been described in cellular and
animal models of ALS-linked to hVAPB. An accumulation of
ubiquitin-positive aggregates that colocalize to a minor degree
with TAR DNA-binding protein (TDP-43)-positive hVAPB
P56S
aggregates was documented in spinal motoneurons of hVAPB
mutant transgenic mice [22]. In HeLa cells, hVAPB
P56S
aggregates were found to be poorly ubiquitinated [21]. A similar
discordant distribution of ubiquitin and hVAPB aggregates was
documented for the two P56S and T46I mutated forms of hVAPB
in NSC34 cells [18]. This is consistent with our analysis, which
shows that the mutated form of hVAPB led to the formation of
ubiquitin aggregates and which seldom colocalized with mutated
hVAPB (Figure 4A). Several hypotheses could explain this partial
colocalization between hVAPB and ubiquitin aggregates. A
proportion of these ubiquitinated proteins could include hVAPB
binding partners [38], or represent a transient aggregation of
ubiquitinated hVAPB, targeted to proteasomal clearing. The
abortive exit of hVAPB mutant from the ER could indeed leads to
its degradation [39]. Accordingly, we found that mutated hVAPB
is degraded faster than the wildtype form and that proteasome
inhibition partially prevents hVAPB
P56S from degradation follow-
ing cycloheximide treatment (Figure 3C). Of note, many ALS-
causing mutations have also been shown to destabilize SOD1
protein [40]. Consistent with previous data [15], when we carried
out an immunoprecipitation of both forms of hVAPB in COS-7
cells co-expressing a haemagglutinin (HA)-tagged ubiquitin [41],
several ubiquitin-positive bands at higher molecular weight were
detected (data not shown). It is noteworthy that an increased
global ubiquitination profile was also observed in cells expressing
the wildtype form of hVAPB, though to a lesser extent that the
mutated hVAPB [15]. However, we could not rigorously evaluate
whether the high-molecular-weight species labeled with ubiquitin
represent poly-ubiquitinated forms of hVAPB or mono- and poly-
ubiquitinated hVAPB binding proteins.
Our data suggest that the degradation of mutated as well as
wildtype hVAPB also occur through alternative mechanisms
independent of the ubiquitin proteasome system. Indeed, it has
been shown that both wildtype and ALS-associated mutated forms
of SOD1 can be degraded by both the proteasomal and autophagy
Figure 5. Overexpression of wildtype and mutated hVAPB impairs proteasome activity. Levels of proteasome YFP reporters in cells co-
transfected (or not) for 36 h with hVAPB
WT, hVAPB
P56S, hVAPA, hSOD1 and Ub-R-YFP (A), Ub-G76V-YFP (B) or CD3d-YFP (C) were examined by Western
blotting using anti-GFP antibodies. (D) Cells were co-transfected with vectors encoding hVAPB
WT, hVAPB
P56S or hVAPA and HA-tagged Fat10, an
ubiquitin-independent signal for proteasomal degradation. Protein extracts were prepared 36 h post-transfection, resolved by SDS-PAGE, Western
blotted and probed with HA, hVAPB, hVAPA and actin antibodies.
doi:10.1371/journal.pone.0026066.g005
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observe any colocalization of autophagy-related (Atg)-8 (LC3) and
Atg12 proteins with hVAPB
P56S aggregates [21]. Consistently, we
did not observe any significant co-localization of hVAPB
P56S
aggregates with the autophagosomal marker LC3, nor the
cleavage and activation of LC3 by Western blot in our
experimental conditions. In addition, stimulation of autophagy
in cells expressing hVAPB
P56S by rapamycin did not significantly
decrease levels of SDS-soluble aggregates (data not shown). Other
options for protein degradation have been demonstrated to
modulate levels of pathogenic proteins. For instance, the insulin-
degrading enzyme and neprilysin are two metalloproteases that
contribute to amyloid b-peptide degradation [43], which therefore
represents attractive therapeutic targets for Alzheimer’s disease
[44]. Another intriguing possibility relates the role of the 20S
proteasome in the selective recognition and degradation of
oxidized proteins in an ubiquitin-independent manner [45].
Oxidative stress plays an important role in ALS pathogenesis
and reactive oxygen and nitrogen species might contribute to
hVAPB modification. The use of proteome technologies will be
pivotal to explore the precise post-translational modifications of
hVAPB.
Two dynamic-quality control compartments have been
described which serve as deposit for misfolded proteins. A
Figure 6. hVAPB-mediated ER stress contributes to the accumulation of proteasome substrates. (A) The immunoreactivity of CHOP in
cells expressing hVAPB
WT and hVAPB
P56S was monitored by Western blotting (36 h after transfection). Thapsigargin treatment (for 16 h) was used as
a positive control for ER stress-dependent CHOP upregulation. (B) Levels of BiP and phosphorylation status of IRE1 were examined by Western
blotting 36 h following the transfection of cells with empty, hVAPB
WT and hVAPB
P56S plasmids. (C) Protein extracts of cells transfected with the
proteasome reporters Ub-R-YFP and Ub
G76V-YFP and treated (or not) for 16 h with the ER stress inducer thapsigargin (10 mM) were subjected to
Western blotting using anti-GFP (referred to as YFP), and anti-CHOP antibodies. (D) Quantification of the YFP immunoreactive bands (C) normalized to
actin signals (arbitrary densitometry units). (E) Salubinal treatment (20 mm) diminished the accumulation of the proteasome reporter (YFP) as
indicated by Western blotting of COS-7 cells co-transfectd with hVAPB
WT or hVAPB
P56S. (F) Differential detergent extraction and Western blot analysis
of ubiquitin in cells expressing hVAPB
WT and hVAPB
P56S and treated or not with salubrinal (20 mM).
doi:10.1371/journal.pone.0026066.g006
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contains ubiquitinated proteins and an insoluble protein deposite
(IPOD) site, which incorporates immobile and non-ubiquitinated
proteins [46]. Quantitative fluorescence recovery after photo-
bleaching experiments demonstrated that the mutant
hVAPB
P56S forms immobile cytosolic aggregates [21]. We could
speculate that the preparation of hVAPB
P56S for clearing occurs
in IPOD centers. However, IPOD compartments colocalize with
autophagic marker (that we and others did not find associated
with mutated hVAPB aggregates) and do not physically interact
with the proteasome (that we demonstrated to be consistently
trapped into hVAPB mutant aggregates). Thus, it is possible that
hVAPB mutant aggregates are directed to other compartments
for their degradation. Collectively, these results underline the
importance of studying the proteolytic machinery that control
hVAPB levels.
Next, we focused our study on how hVAPB buildup might cause
UPS impairment. Recently, we found that the viral-promoted
expression of both wildtype and mutated hVAPB selectively
triggered death of motoneurons. It was intriguing that both forms
of hVAPB elicited an ER stress response, as examined by the
quantification of fluorescent intensity of phosphorylated IRE1
immunolabelling, in embryonic motoneurons. The functional
involvement of ER stress in motoneuron death was illustrated by
the neuroprotective effect of salubrinal against AAV-mediated
overexpression of hVAPB
WT and hVAPB
P56S [17]. ER stress,
which was demonstrated to compromise UPS, was of a particular
interest [30]. Unfortunately, the limited quantities of materials
obtained from primary culture of motoneurons preclude many
biochemical studies. Here, we confirmed that in non-human
primate cells the expression of hVAPB
WT and hVAPB
P56S led to
ER stress (Figure 6A–B), giving us the opportunity to investigate
Figure 7. Wildtype and mutated hVAPB associate with the proteasome. (A) Both hVAPB
WT and hVAPB
P56S colocalize with the alpha 5
subunit of the proteasome, as indicated by the double immunostaining of cells transfected with empty, hVAPB
WT and hVAPB
P56S vectors. Images
were acquired with the same exposure time and camera settings. White arrows indicates non-transfected cells. Scale bar, 20 mm. (B–C) hVAPB
WT and
hVAPB
P56S were immunoprecipitated from COS-7 cells transfected with hVAPB
WT, hVAPB
P56S, myc-tagged Sar1, myc-tagged Arf1, myc-tagged hSOD1
and hVAPA. Endogenous alpha 5 (B) or alpha 1–7 (C) subunits of the proteasome that co-immunoprecipitated with hVAPBs was detected by Western
blotting using specific antibodies. hVAPB, myc (Sar1, Arf1 and hSOD1) and hVAPA input levels are shown. Immunoprecipitation of alpha 1–7 by Rpt2
served as a positive control.
doi:10.1371/journal.pone.0026066.g007
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has previously been demonstrated that ER stress, elicited by
thapsigargin or tunicamycin, impairs degradation of UPS reporter
substrates, although ER stressors induce a modest rather than a
complete impairment of UPS functions [30]. Correspondingly, we
found that the overexpression of hVAPB
WT and hVAPB
P56S,
which leads to the robust induction of the ER stress marker
CHOP, BiP and phosphorylation of IRE1, induce an accumula-
tion of UPS reporter substrates. However, the inhibition of ER
stress by salubrinal did partially abrogate UPS impairment
(Figure 6E–F). Since our work reveals that an ALS-causing gene
impairs proteasome function partially through the ER stress
pathway, it is conceivable that the partial but long-lasting
impairment of proteasome function subsequent to a chronic ER
stress contributes to the progressive and pernicious accumulation
of proteins. The mechanisms by which ER stress leads to
proteasome dysfunction remains to be examined in future studies.
It has been demonstrated that an ER stress response take place
early in the history of the disease, well before the first clinical
symptoms and the administration of salubrinal in SOD1 mutant
mice conferred therapeutic benefit [47]. From the same study, it
was found that an augmentation of ubiquitin signals in ALS-
vulnerable as well as resistant motoneurons shortly precedes a
marked ER stress response that selectively takes place in the ALS-
vulnerable population. It is conceivable that the impairment of
proteasome activity elicited by the accumulation of hVAPB
WT and
hVAPB
P56S precedes the ER stress response. However, our data
also suggest that the ER stress induced by the overexpression of
wildtype and mutated hVAPB contribute to the impairment of
UPS activity (Figure 6), which can in turn elicits an ER stress
response. An amplification process that would selectively manifest
in vulnerable motoneurons prone to ER stress [47], could
contribute to ALS pathogenesis. A better understanding of ER
stress signaling will therefore be instrumental for the development
of effective therapies for motoneuron disease as well as other
conformational disorders including Alzheimer’s and Parkinson’s
disease, in which ER stress also play an important role [48].
Our results also provide evidence that mutated hVAPB interacts
and partitions the 20S proteasome into cytoplasmic aggregates
(Figure 7A–C). This may indicate that a limited availability of the
proteasome caused by its sequestration into aggregates could lead
to the accumulation of ubiquitin and Fat10 conjugates (Figure 4C–
D and 5D). Neurodegenerative disorders have been reported to be
associated with accumulation of proteasome into neuronal
inclusions. For example, the 20S proteasome localize at the site
of mutant Ataxin-1 aggregation in neurons of spinocerebellar
ataxia type 1 patients [49]. In the brain of Lafora disease patients,
a recruitment of the 20S proteasome has been observed in
polyglucosan aggregates [50]. Of particular relevance to our study,
a focal and intense accumulation of 20S proteasome was observed
in spinal motoneurons of sporadic ALS patients [51]. Ubiquitin-
positive aggregates can be hypothesized as a challenging substrate
for the proteasome, leading therefore to an impairment of the
proteolytic machinery. However, in our study, ubiquitinated
aggregates poorly colocalize with mutated hVAPB, while the
20S proteasome is mainly associated with hVAPB
P56S aggregates.
This suggests that the trapping of the proteasome by mutated
hVAPB would occur independently of its ubiquitination. Consis-
tent with this, the wildtype form of hVAPB interacts with the
proteasome and leads to its retention at the ER (Figure 7A–C), and
this could compromise its activity resulting in the accumulation of
ubiquitin- or Fat10–conjugated proteins. We observed that the
overexpression of wildtype hVAPB led to the accumulation of the
ERAD substrate CD3d (Figure 5C). CD3d-YFP, as well as the two
others cytosolic substrates, allow us to show an impairment of the
proteosomal activity. However, we cannot rule out the possibility
that the ERAD machinery, which mediates the translocation of
misfolded proteins from the ER to the cytoplasm for their
subsequent degradation by the UPS, is also compromised [52].
Inhibition of ERAD by SOD1 mutant, through its interaction with
Derlin-1, a functional component of the ERAD, has been
proposed to trigger ER stress [53]. An impairment of ERAD
function by hVAPB would contribute to the accumulation of
misfolded proteins in the ER, eliciting therefore an ER stress
response. As discussed above, such a feedback amplification
mechanism would progressively lead a more global disturbance of
protein homeostasis.
Biogenesis of the proteasome, which is a highly ordered
multistep process implicating several assembly and maturation
factors, mainly takes place at the ER [54,55]. An intriguing
working hypothesis is that hVAPB interacts with the assembly
machinery at the ER to contribute to proteasome formation. The
abnormal presence of wildtype hVAPB as well as the mutated
protein, as long as it retains its ability to insert into the ER
membrane and form cytoplasmic inclusion continuous with the
ER [19], might interfere in the biogenesis program. This could
explain the neurotoxicity observed in motoneurons following the
overexpression of both wildtype and mutated hVAPB [17]. It
would be interesting to examine whether hVAPB and other ALS-
causing gene products modify the assembly and activation
program of the proteasome in motoneurons.
Materials and Methods
Cell culture
COS-7 cells (American Type Culture Collection, ATCC,
Manassas, VA, USA) were cultured in 10 cm diameter dishes
for immunoprecipitation experiments, in 6-well plates for Western
blot analysis or on 12 mm diameter glass coverslips (placed in 24-
well plates) for immunostaining. Cells were maintained in
Dulbecco Modified Eagle Medium (DMEM, Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum and
penicillin (50 U/ml) and streptomycin (50 mg/ml)(Invitrogen).
Cells were plated in different culture dishes at the density of
20,000 cell per cm
2, transfected the day after with 10 mgo f
indicated expression vector for 10 cm diameter dishes, 3 mg for 6-
well plates and 0.8 mg for 24-well plates using Fugene 6
transfection reagent following the manufacturer’s instruction
(Roche diagnostics, Indianapolis, IN, USA). An equimolar ratio
was used for co-transfection experiments. We transfected corre-
sponding empty expression vectors for control samples. We
reproducibly found by PCR analysis our cell line to be free of
mycoplasma contamination.
Reagents
Cycloheximide and MG-132 were purchased from Sigma-
Aldrich (St Louis, MO, USA), salubrinal was purchased from
Enzo life sciences (Lausen, Switzerland, USA) and thapsigargin
from Millipore (Calbiochem, Millipore, Bedford, MA, USA).
Expression vectors
hVAPB
WT, hVAPB
P56S and hVAPA coding sequences were
placed under the control of the human ubiquitin c promoter as we
previously described (pUbc-hVAPB
WT, pUbc-hVAPB
P56S and
pUbc-hVAPA)[17]. The Arf1 coding sequence was amplified from
mouse spinal cord using the following sense primer 5’-AC-
CATGGGGAATATCTTTGCAAACCTC-3’ and antisense
primer: 5’-CTTCTGGTTCCGGAGCTGATTAGAC-3’ as pre-
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pCR2.1 vector (Invitrogen). Arf1 cDNA was then incorporated in
frame with a myc tag sequence into the pCS2+-myc expression
vector. The probity of the sequence was confirmed by sequencing.
The myc-Sar1 (pCS2+-myc-Sar1) expression vector has been
described in [56].
b-COP-CFP construct was kindly provided by Irina Majoul
[23], Sec23-YFP by David Stephens [24], GFP-Ubi and GFP-
UbiAA by Michel Bouvier [26], HA-ubiquitin by Simone Diestel
[41], HA-Fat10 by Marcus Groettrup [32]. Ub-R-YFP, Ub
G76V-
YFP and CD3d-YFP constructs were obtained from Addgene
(Cambridge, MA, USA). Myc-hSOD1 expression vector was
obtained by cloning hSOD1 coding sequence [57]. All plasmids (at
the exception of hVAPB
WT, hVAPB
P56S and hVAPA as
mentioned above), constitutively express the indicated cDNA
from the cytomegalovirus (CMV) promoter.
Immunocytochemistry
Immunofluorescence staining was performed as we previously
described [17,58]. Briefly, cells were cultured onto glass coverslips
and fixed in 3.7% formaldehyde for 20 min at room temperature
(RT). After three washes in phosphate-buffered saline (PBS), cells
were incubated for 1 h in PBS containing 0.1% Triton X-100, 4%
bovine serum albumin (BSA) and 5% heat-inactivated donkey
serum (blocking solution). Cells were incubated overnight at 4uC
in the blocking solution containing the following primary
antibodies: anti-KDEL (10C3, Enzo life sciences, 1:400), anti-
ERGIC-53/p58 (E1031, Sigma-Aldrich, 1:200), anti-GM130
(612008, BD Biosciences, Franklin Lakes, NJ, USA, 1:300) anti-
alpha5 proteasome subunit (MCP196, Enzo life sciences, 1:250).
Cells were washed 4 times for 5 min each with PBS, incubated
with the appropriate fluorescent-conjugated secondary antibody
(Invitrogen), washed, and mounted in moviol containing 1,4-
diazobicyclo-[2.2.2]-octane (DABCO, Sigma-Aldrich). Images
were collected using either an Olympus BX50WI laser-scanning
confocal or a Zeiss ApoTome microscope.
Differential detergent extraction
The cells were washed with ice-cold PBS, scraped and
centrifuged at 1,5006g for 5 min at +4uC. Cell pellet was first
resuspended in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM
EDTA, 2 mM EGTA and 1% Triton X-100 and incubated on ice
for 20 min. Cells were centrifuged at 120,0006g for 30 min at
4uC. The collected supernatant constituted the Triton X-100-
soluble fraction. The pellet was then resuspended in 50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA and
1% SDS and centrifuged at 120,0006g for 30 min at 4uC, in order
to collect the supernatant, referred to as the SDS fraction. Finally,
the pellet was resuspended in urea lysis buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA and 8 M
urea) and constituted the urea-soluble fraction.
Western blotting
Western blotting was carried out on cell lysates using the
protocol previously described [17,58]. Otherwise indicated, total
proteins were extracted using SDS lysis buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA and 1%
SDS) supplemented with a protease inhibitor cocktail (Roche
diagnostics). Protein concentration was determined using the BCA
kit following manufacturer’s instructions (Pierce, Rockford, IL,
USA). After a 5 min denaturation step at 95uC in Laemmli buffer
(62.5 mM Tris-HCl pH6.8; 2% SDS; 10% glycerol; 2.5% b-
mercaptoethanol; 0.0075% bromophenol blue), protein samples
were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and blotted to nitrocellulose mem-
branes (Schleicher and Schuell, Whatman International Ltd,
Springfield Mill, UK). The membranes were washed with PBS
containing 0.1% Tween-20 (PBST) and blocked in PBST with 5%
non-fat dry milk. The following primary antibodies were diluted in
PBST with 3% BSA at concentrations and applied overnight at
+4uC: anti-hVAPB (DIM705; previously described in [17];
1:2,000), anti-actin (AC-40; Sigma-Aldrich; 1:4,000), anti-ubiqui-
tin (Z0458; DAKO, Glostrup, Denmark; 1:1,000), anti-HA
(16B12; Covance; 1:1,000), anti-GFP (TP401; Torrey Pines
Biolabs, East Orange, NJ, USA; 1:2,000), anti-VAPA (K15; Santa
Cruz Biotechnology, Santa Cruz, CA, USA; 1:2,000), anti-SOD1
(574597; Calbiochem; 1:2,000), anti-myc (9E10; SantaCruz
Biotechnologies; 1:2,000), anti-CHOP (F-168; Santa Cruz Bio-
technologies; 1:1,000), anti-BiP (3177, Cell Signaling Technology,
1:1,000), anti-phospho-IRE1 (ab48187, Abcam, Cambridge, MA,
USA, 1:1,000), anti-alpha5 (MCP196; Enzo life sciences; 1:1,000)
and anti-alpha1-7 (MCP231; Enzo life sciences; 1:1,000). Proteins
were then detected using horseradish peroxidase-conjugated
secondary antibodies (DAKO), chemiluminescent horseradish
peroxidase substrate (Millipore) and X-MR films (Kodak). When
required, immunoblot images were quantified by densitometric
analysis of immunoreactive bands using the ImageJ software
(National Institutes of Health, USA) and normalized relative to
their respective actin signals.
Immunoprecipitation
Cells were washed twice with cold PBS and lysed on ice for
10 min in IP buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl,
5m ME D T A ,5m ME G T A ,2m MA T P ,1 0 %g l y c e r o la n d1 %
Triton X-100) with proteases inhibitors. Lysates were pre-
cleared by a 5 min centrifugation at 1006g and then protein
concentration was determined by a modified Bradford reaction
(Bio-rad laboratories, Hercules, CA, USA). 1 mg of total
proteins (adjusted to a volume of 500 ml with IP buffer) were
incubated overnight at +4uC with appropriate primary anti-
bodies: hVAPB (1:100), hVAPA (1:500), myc (1:500), Rpt2
(1:250) and Protein A or G sepharose beads (20 mlp a c k e d
beads, GE Healthcare, Buckinghamshire, UK). Immunocom-
plexes were collected by centrifugation for 1 min at 1,0006g at
+4uC. After three rounds of washes with 800 ml of IP buffer
each, the immunoprecipitated proteins were denatured 5 min at
95uC in Laemmli buffer and resolved by SDS-PAGE as
described for Western blotting.
Statistical analyzes
Data represent the mean values 6 standard deviation (S.D) of at
least three independent experiments, each done at least in
duplicate. Statistical significance was determined by an unpaired
two-tailed Student’s t test using GraphPad Prism (GraphPad
Software, La Jolla, CA, USA). Significance was accepted at the
level of P , 0.05. P values are expressed as *P , 0.05, **P , 0.01
and ***P , 0.001.
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